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The term myoﬁbrillar myopathies (MFM) refers to uncommon 
neuromuscular disorders that pathologically are characterized by 
myoﬁbrillar degeneration and ectopic expression of several pro-
teins. MFM are partly caused by mutations in genes that encode 
mainly Z-disk-related proteins (desmin, αB-crystallin, myotilin, 
ZASP, ﬁlamin C and BAG3). We reviewed clinical, light and elec-
tron microscopy, immunohistochemistry, immunoblotting and ge-
netic ﬁndings of 21 patients with MFM (15 unrelated patients and 
three pairs of brothers) investigated at our neuromuscular center. 
MFM patients begin to show symptoms at any age, from juve-
nile to late adult life and present a different distribution of muscle 
weakness. Cardiac involvement and peripheral neuropathy are 
common. Typical histological features include focal areas with re-
duction/loss of ATPase and oxidative enzyme activity, and amor-
phous material (eosinophilic on hematoxylin and eosin and dark 
blue on Engel-Gomori trichrome) in these abnormal ﬁber areas. 
Electron microscopy shows disintegration of myoﬁbrils starting 
from the Z-disk and accumulation of granular and ﬁlamentous 
material among the myoﬁlaments. Immunohistochemical stud-
ies demonstrate focal accumulation of desmin, αB-crystallin and 
myotilin in abnormal muscle ﬁbers while immunoblot analysis 
does not highlight differences in the expression of these proteins 
also including ZASP protein. Therefore, unlike immunoblot, im-
munohistochemistry together with light and electron microscopy 
is a useful diagnostic tool in MFM. Finally three of our 21 patients 
have missense mutations in the desmin gene, two brothers carry 
missense mutations in the gene encoding myotilin, one has a mis-
sense mutation in αB-crystallin, and none harbour pathogenic 
variations in the genes encoding ZASP and BAG3.
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Introduction
Myofibrillar myopathies (MFM) are uncommon in-
herited or sporadic progressive neuromuscular disorders 
with clinical and genetic heterogeneity (1, 2). MFM are 
morphologically defined by foci of myofibril dissolu-
tion, accumulation of myofibrillar degradation products, 
and ectopic expression of multiple proteins including 
desmin, αB-crystallin, dystrophin, myotilin, sarcogly-
cans, neural cell adhesion molecule (NCAM), plectin, 
gelsolin, ubiquitin, filamin C, and congophilic amyloid 
material (3-5).
To date, mutations in six genes are known to cause 
MFM, but these account for less than half of patients 
with a diagnosis of MFM (1). These genes encode mainly 
sarcomeric Z-disk or Z-disk-related proteins and the mu-
tated proteins are usually found inside the aggregates: de-
smin (6), αB-crystallin (7), myotilin (8), Z-band alterna-
tively spliced PDZ motif containing protein (ZASP) (9) 
and  filamin  C  (10). Additionally,  mutations  in  BAG3 
have recently been shown to cause MFM (11). Despite 
the identification of several mutations in different genes, 
the typical histological features are observed in all pa-
tients (12). To date, the mechanisms leading to protein 
aggregation are not fully understood and recent studies 
proposed that the fiber abnormalities in MFM probably 
are a common step of a stress-induced pathway, triggered 
by different stimuli (13, 14).
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We here describe our clinical, light and electron mi-
croscopy,  immunohistochemistry,  immunoblotting  and 
genetic analysis findings in 21 MFM patients investigated 
at our neuromuscular center.
Patients and methods
Patients
Twenty-one patients were diagnosed as affected with 
MFM at our neuromuscular center. The cohort included 15 
unrelated patients and three pairs of brothers. Patients were 
studied at clinical, morphological, biochemical and genetic 
level; clinical and genetic studies were done in all 21 cases 
and muscle biopsy was performed in 20 patients.
Histology and histochemistry
Muscle samples were snap frozen in liquid nitrogen-
cooled isopentane. Serial 8-μm-thick cryosections were 
stained  with  haematoxylin  and  eosin  (H&E),  Engel-
Gomori  trichrome,  adenosine  triphosphatase  (ATPase, 
pre-incubation at pH 4.3, 4.6 and 10.4), succinate dehy-
drogenase (SDH), cytochrome c oxidase (COX), reduced 
nicotinamide  adenine  dinucleotide  (NADH),  periodic 
acid-Schiff (PAS) with diastase digestion, Sudan black 
and acid phosphatase.
Electron microscopy
A small fragment of muscle tissue was fixed in 4% 
glutaraldehyde in phosphate buffer, post-fixed in 2% os-
mium tetroxide, dehydrated and embedded in Spurr resin. 
Semithin sections were stained with toluidine blue and 
PAS. Ultrathin sections were stained with uranyl acetate 
and lead citrate and examined in a Zeiss EM 109 electron 
microscope.
Immunohistochemical studies
Immunohistochemistry was performed on serial 6.5-
μm-thick sections with antibodies to desmin, αB-crystallin 
and myotilin; the reactions were revealed by immunofluo-
rescence methods, as previously described (15). Controls 
were muscle biopsies from subjects who were ultimately 
deemed to be free from muscle diseases. To control stain-
ing specificity the primary antibody was omitted or re-
placed with nonimmune sera at the same concentration.
SDS-PAGE electrophoresis and immunoblot analysis
The expression of desmin, αB-crystallin, myotilin and 
ZASP was evaluated by one-dimensional immunoblotting 
as described (15). Briefly, twenty 20-μm-thick frozen mus-
cle sections were homogenized with a lysis buffer (50 mM 
Tris/HCl, 150 mM NaCl, 1 mM EDTA, 0.1% SDS, 1% NP-
40, 0.5% deoxycholic acid, pH 7.5 and including protease 
inhibitors), sonicated and centrifuged at 1500 g for 10 min. 
Protein concentration was determined in the supernatants 
with the Bradford method. Aliquots corresponding to 20 μg 
of proteins were loaded on a 10% T polyacrylamide gel and 
separated by electrophoresis. Samples were transferred to 
a nitrocellulose membrane that was blocked with non-fat 
dried milk for 60 min at room temperature and incubated 
overnight at 4°C with the specific antibodies. After inter-
vening washes, the membrane was incubated with second-
ary antibody conjugated to horseradish peroxidase (Amer-
sham Pharmacia Biotech). Bands were visualized with the 
ECL Advance Western Blotting Detection Kit (Amersham 
Pharmacia Biotech, Buckinghamshire, UK). Protein load-
ing was confirmed by Coomassie staining of the gel. Bands 
were quantified densitometrically using the Quantity One 
software (Bio-Rad).
Genetic studies
DNA was extracted by standard methods from the 
whole blood obtained after informed consent for diag-
nostic procedures. In all MFM patients was performed 
at genomic level the screening for mutations in the fol-
lowing genes: Desmin (DES, NCBI Reference Sequence: 
NG_008043.1), Myotilin (MYOT, NCBI Reference Se-
quence:  NG_008894.1),  Crystallin,  alpha  B  (CRYAB, 
NCBI  Reference  Sequence:  NG_009824.1)  LIM  do-
main  binding  3  (LDB3,  NCBI  Reference  Sequence: 
NG_008876.1)  and  BCL2-associated  athanogene  3 
(BAG3, NCBI Reference Sequence: NG_016125.1).
We PCR amplified all the coding exons, the splice site 
junctions and 100bp of flanking introns (primers sequences 
available upon request); PCR reactions were carried out in 
a volume of 25 μl containing 25 ng of DNA template and 
2.5U Taq polymerase (Invitrogen), 1X Buffer, 0.75 mM 
MgCl2, 200 μM dNTPs, 0,5-1 μM each primer.
The amplification conditions were as follows: 94°C 
initial  denaturation  (5  min),  94°C  denaturation  (45s), 
60°C (45s) annealing, 72°C (60s) extension for 30 cycles, 
72°C (7 min) final extension.
The amplified PCR products were analyzed by direct 
sequencing on an automatic sequencer (ABIPRISM 3130, 
Applied Biosystems, Foster City, CA). All the sequence 
variations were annotated taking the first base of the Met 
codon counted as position 1 in the Reference Sequence.
Results
Clinical characteristics of patients
A total of 21 MFM patients from 18 families were 
studied. The male to female ratio was 1.6; thirteen pa-Clinical, morphological and genetic studies in a cohort of 21 patients with myofibrillar myopathy
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tients were men and eight were women. The age of dis-
ease onset ranged from 16 to 78 years (mean, 42.8 years; 
median 55 years) and the age at diagnosis varied from 
30  to  79  years  (mean,  52.1  years,  median  53  years). 
Seven patients reported a family history suggestive of 
neuromuscular disorders and among these three pairs of 
brothers were present.
The  symptoms  reported  at  the  time  of  muscle  bi-
opsy consisted of muscle fatigue, 12; slowly progressive 
weakness, nine; muscle wasting, seven; myalgia and/or 
cramps, six; myotonia, one; dysphagia and/or dysphonia, 
four; dyspnoea, four; palpitations, four; paresthesias and/
or hypoesthesias, seven.
Clinical examination revealed muscle weakness in 17 
patients; the remaining four patients complained of my-
algias associated with elevated serum CK (three patients) 
or had similarly affected family members (one patient). 
The distribution of weakness at the time of diagnosis was 
different in the 17 patients. In four, the weakness involved 
only axial muscles; two patients had weakness of the par-
avertebral muscles both at thoracic and at cervical level; 
the other two presented weakness of the paravertebral 
muscles at thoracic level. Thirteen patients had weakness 
of limb muscles; in eight, the weakness involved both 
proximal and distal limb muscles; in four, the weakness 
was only proximal, and in two it was only distal. At fol-
low-up evaluation, in two patients the axial muscle weak-
ness spread to limb muscles; in five weakness localized to 
the proximal or distal limb at the time of diagnosis, later 
extends distally or proximally.
Among 10 patients who underwent to heart assess-
ment, seven had cardiac involvement. Two of these pa-
tients had signs of congestive heart failure and arrhyth-
mia; two had signs of congestive heart failure without 
arrhythmia; and three had arrhythmia without congestive 
failure. Arrhythmias included paroxysmal supraventricu-
lar tachycardia in three patients, left bundle branch block 
in two affected brothers with desmin mutation, and sinus 
block in one patient. Two patients with arrhythmias un-
derwent pacemaker implantation.
Serum CK was determined in 12 patients and the 
mean level was found to be 4-fold above the upper normal 
limit (range, from normal to 9-fold).
Nerve  conduction  studies  and  electromyography 
(EMG) was performed in 18 patients. Abnormal spon-
taneous  activity  consisting  of  fibrillation  potentials, 
positive sharp waves and complex repetitive discharges 
was recorded in three patients; one of these (the patient 
with the clinical symtom of myotonia) had also myot-
onic discharges. Ten patients had low-amplitude, short-
duration polyphasic motor unit potentials (MUPs); two 
high-amplitude, long-duration MUPs and four normal 
MUPs.
Histology and histochemistry
Histological  analysis  documented  myopathic  fea-
tures in all specimens. Muscle biopsies from all MFM 
patients showed areas with a loss or reduction of ATPase 
Figure  1.  Histological  findings  in  myofibrillar  myopa-
thies. Muscle fibers with amorphous material that stains 
eosinophilic on hematoxylin and eosin (A) and dark blue 
on  Engel-Gomori  trichrome  (B).  Several  muscle  fibers 
with loss of NADH activity (C).G. Vattemi et al.
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and oxidative enzyme activity (COX, SDH and NADH) 
(Fig. 1). These abnormal areas had variability in number, 
shape and size, were randomly distributed inside the mus-
cle fibers. Many abnormal fiber regions harboured amor-
phous material that was eosinophilic on hematoxylin and 
eosin staining and dark blue on Engel-Gomori trichrome 
(Fig. 1). Slight fiber size variation was observed in 14 
patients. Atrophic  angulated  fibers,  singly  or  in  small 
groups, were of either histochemical type and occurred 
in 13 specimens. Type 1 fiber predominance was found 
in five cases and type 2 fiber predominance only in one 
patient. Sparse small vacuoles, rimmed or not, appeared 
in half of the specimens; cytoplasmic bodies were infre-
quent but in one patient they were the only histological 
abnormality. Necrotic fibers were rare and isolated on a 
given section and were present in five cases, in five muscle 
biopsies there was also fiber degeneration. Regenerating 
fibers were uncommon (three cases). In one biopsy speci-
men there was an endomysial inflammatory infiltrate. In-
crease of endomysial connective tissue with occasional 
adipocyte infiltration was observed in eight patients. In-
ternal nuclei and/or fibers subdividing by splitting were 
present in four cases. The muscle fiber lipid and glycogen 
content was normal.
Electron microscopy
Ultrastructural examination showed single or mul-
tiple focal areas of different size with myofibrillar dis-
ruption, streaming of Z-disk, and abundant granulofila-
mentous material which was either diffusely interspersed 
among the myofibrils or located under the sarcolemma 
(Fig. 2). On longitudinal sections, the granulofilamen-
tous material seemed to derive from Z-disk; occasionally 
it was aggregated to form spherical structures. Vacuoles 
containing cytoplasmic degradation products were com-
mon and typical cytoplasmic bodies were rare. There was 
no  evidence  of  ultrastructural  abnormalities  involving 
other cellular structures, in particular nuclei, T-tubules 
and sarcoplasmic reticulum.
Immunohistochemistry
In  all  muscle  biopsies  from  patients  with  MFM, 
abnormal fibers with focal areas of increased reactivity 
for  desmin,  αB-crystallin  and  myotilin  were  observed 
(Fig. 3). These areas were single or multiple, variable in 
shape and size and unevely distributed within the fibers. 
The percentage of abnormal fibers was variable between 
the different cases examined and ranged between 2 and 
15% of the total muscle fibers. The αB-crystallin deposits 
resembled the desmin and myotilin deposits in distribu-
tion and staining intensity but they appeared to be more 
frequent than the other two proteins.
Figure 2. Ultrastructural features of myofibrillar myopa-
thies. Granulofilamentous material diffusely interspersed 
among the myofibrils.
Figure 3. Immunohistochemistry for αB-crystallin, de-
smin and myotilin in myofibrillar myopathies. Focal accu-
mulation of αB-crystallin (A), desmin (B) and myotilin (C) 
in several muscle fibers.Clinical, morphological and genetic studies in a cohort of 21 patients with myofibrillar myopathy
125
SDS-PAGE electrophoresis and immunoblot analysis
In normal and MFM muscle biopsies desmin migrat-
ed as a 53 kDa band, αB-crystallin as a 20 kDa band and 
myotilin as a 55 kDa band. ZASP protein instead showed 
two bands at the molecular weight of 78 and 32 kDa. The 
intensity of all bands was similar in muscle of patients 
and control subjects (Fig. 4).
Genetic Studies
In  the  Desmin  gene  we  identified  in  two  affected 
brothers the c. 20 C > T substitution in heterozygosis (S7F) 
previously unreported and in another patient the c. 1360 
C > T substitution in heterozygosis (R454W) reported as 
pathogenetic (16). The Crystallin, alpha B gene analysis 
revealed in one patient in heterozygosis the c.460G > A 
mutation (G154S) reported as pathogenetic (17). In two 
affected brothers the analysis of myotilin gene showed 
the known pathogenetic mutation c. 116 C > T (S39F) in 
heterozygosis (18). None of our MFM patients harboured 
pathogenic variations in the LIM domain binding 3 gene 
and in the BCL2-associated athanogene 3. In all the genes 
analyzed we identified several known polymorphism both 
in heterozygosis and in homozygosis.
Discussion
We present here a retrospective analysis of data de-
rived from 21 patients with MFM investigated at our neu-
romuscular center. MFM patients begin to show symptoms 
at any age, from juvenile to late adult life and diagnosis is 
delayed compared to the age of the first appearance of the 
symptoms. In our cohort onset was not observed until af-
ter reaching 16 years of age. From clinical point of view, 
we should emphasize that symptoms reported at the time 
of diagnosis are extremely variable and muscle weakness 
is not documented in all our patients at the time of be-
ing subjected to muscle biopsy. Cardiac involvement is 
common occuring in 39% of our patients. There is an in-
creased incidence of electrocardiographic abnormalities, 
including atrial arrhythmias, atrioventricular conduction 
defects and bundle branch block. Congestive heart failure 
is not uncommon; in our series it was documented in 4 of 
21 patients. In our study we also found a frequent involve-
ment of peripheral nervous system. Clinical signs and/or 
EMG findings of peripheral neuropathy are present in ap-
proximately 44% of our cohort and even in one patient 
sensory deficits are presenting symptoms.
A broad spectrum of light microscopic changes rang-
ing from mild to severe abnormalities was documented in 
all muscle biopsy specimens of our patients. The typical 
pathological findings include: (1) focal areas with either 
reduction/loss of NADH, SDH and COX staining or de-
creased ATPase activity present in almost all patients; (2) 
amorphous material that stains eosinophilic on hematox-
ylin and eosin and dark blue on Engel-Gomori trichrome 
in most of these abnormal fiber areas; (3) rimmed and 
non-rimmed vacuoles observed in 45% of cases and cy-
toplasmic bodies in only 10%. In addition to myopathic 
features,  the  presence  of  small  angulated  fibers  of  ei-
ther histochemical type which may occur singly or in 
groups suggest a neurogenic process; these findings were 
present in more than 60% of patients. Although none of 
these histological abnormalities is specific for MFM, the 
combination of these changes outline the diagnosis (2). 
Electron microscopic studies documented disintegration 
of myofibrils starting from the Z-disk and accumulation 
of granular and filamentous material widely distributed 
among the myofilaments. These abnormalities observed 
at ulrastructural level suggested the temporal sequence 
of pathological events occurring in MFM (12). Initially 
there is a breakdown of myofibrils beginning at the Z-disk 
owing to loss of the normal architecture of the myofibrils 
and disruption of intermediate filaments; then deposits of 
filamentous material accumulate in different shape and 
size displacing membranous organelles; and ultimately 
membranous  organelles  are  sequestered  in  autophagic 
vacuoles.
Our immunohistochemical data demonstrated the fo-
cal accumulation of desmin, αB-crystallin and myotilin 
in muscle fibers of all patients and thus confirm that im-
munohistochemistry is a sensitive tool to detect protein 
aggregation in MFM muscle specimens (2). These depos-
its correspond to the abnormal fiber regions without, or 
with reduced, ATPase and/or oxidative enzyme activity 
Figure 4. Immunoblot for desmin, αB-crystallin, myotilin 
and ZASP. The intensity of all bands was similar in both 
patients’(P)  and  controls’(C)  muscles.  Coomassie  blue 
staining was used to assess protein loading.G. Vattemi et al.
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and are higly variable in terms of number, shape, size and 
intracellular localization. While in some specimens pro-
tein aggregates are multiple, widespread within muscle 
fibers and affect up to 15% of all fibers, in others these 
inclusions are singly, tiny and only in a small percentage 
of fibers. In most cases aggregates are immunoreactive 
for all three proteins but αB-crystallin deposits are more 
numerous than the other two.
In contrast to light and electron microscopy, immu-
noblot analysis is not useful and informative for the di-
agnosis of MFM because in muscle of MFM patients it 
does not highlight differences in the expression of mostly 
commonly proteins observed in the intracellular depos-
its. These data seem to suggest, therefore, that the total 
content of proteins in MFM muscle might be unchanged 
when compared to normal controls and are in agreement 
with  the  previous  demonstration  that  in  patients  with 
MFM there is no increased gene transcription of different 
proteins that are believed involved in the pathogenesis of 
this disease including desmin and αB-crystallin (19).
Finally we identified genetic mutations in six out of 
21 patients with MFM: three from two families had dif-
ferent mutations in the desmin gene while in three other 
cases, which also belonged to two different families, mu-
tations in the genes encoding myotilin (in two affected 
brothers) and alpha crystallin B chain were found. Instead 
in our cohort we did not find any pathogenic variations in 
the genes encoding LIM domain-binding protein 3 and 
BAG3. One of the four reported mutations was never de-
scribed in the literature and in particular the missense mu-
tation S7F in the desmin gene identified in two affected 
brothers; the other three missense mutations including 
one in the gene encoding desmin (R454W), one in the 
myotilin gene (S39F) and the other in the gene of αB-
crystallin (G154S) have already been documented and 
considered as pathogenetic (16-18). Therefore, the ge-
netic basis of MFM was established in only 28% of our 
cases and these data are consistent with those reported in 
other studies (20).
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